Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Reuters NewMedia - Wednesday October 25, 2000
The immune booster, interleukin-2 (IL-2), increased the number of CD4 T-cells, the immune system helper cells attacked by HIV, the researchers said.
"We believe our findings point to a new strategy for helping people with very low T-cell counts fight advanced HIV disease," Dr. Ronald Mitsuyasu, director of the University of California Los Angeles AIDS Research and Education Center, said in a statement.
Speaking to the 5th International Congress on Drug Therapy in HIV Infection in Glasgow, Scotland, Mitsuyasu said his team added IL-2 to the drug cocktails of 164 patients. Most patients got the IL-2 boost, while 55 got the drug cocktail, known also as highly active antiretroviral therapy (HAART), alone.
The patients who received the combination therapy had a dramatic increase in new CD4 cells. This is usually linked with better health in HIV patients.
The patients also had fewer episodes of AIDS-related illnesses, such as Kaposi's sarcoma, lymphoma and pneumonia, the researchers said.
"We found it remarkable that we could observe a measurable difference in opportunistic infections after only 60 weeks," Mitsuyasu said.
Other researchers have also found that adding IL-2 to drug cocktails helps the patients' immune systems.
The National Institutes of Health has licensed the technology to Chiron Corp. of California.
Chiron says it plans an international Phase III trial for the IL-2 treatment, the last stage of patient testing before a company seeks U.S. Food and Drug Administration web (FDA) approval for a drug. One drawback is that IL-2 must be given in an injection, but patients can do this at home.
001025
RE001019
Copyright © 2000 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .